This GRID accelerator project will mature our wearable mechanostimulation system from benchtop prototype to translation-ready device, incorporating critical parameter optimization and user connectivity components necessary for large-scale clinical trials in patients with spasticity. Spasticity causes involuntary muscle stiffness and contractions in over 12 million individuals worldwide, and is accompanied by a debilitating hindrance to movement, lack of independence, and chronic pain. The global market for treatment of spasticity was valued at $13.1 billion in 2023 and is projected to exceed $28.4 billion by 2030. Current approaches are invasive or time-consuming with modest to low efficacy.